Search results
Analysts Expect Moderna's First-Quarter Sales To Plummet 95% — Is Moderna Stock A Sell?
Investor's Business Daily· 4 days agoA Phase 3 study is already underway with the initial results expected later this decade. But at...
Merck (MRK) Q1 Earnings Top, Cancer Drug Keytruda Boosts Sales
Zacks via Yahoo Finance· 3 days agoLagevrio (molnupiravir) generated sales of $350 million in the first quarter, down 5% year over...
How Should You Play Merck (MRK) Stock Ahead of Q1 Earnings?
Zacks via Yahoo Finance· 6 days agoInvestor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine,...
Merck (MRK) Q1 2024 Earnings Call Transcript
Motley Fool via Yahoo Finance· 3 days agoTurning...grew 24% to $6.9 billion driven by increased uptake from earlier-stage cancers and continued strong demand from metastatic indications....
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 4 days agoNew York, USA, April 24, 2024 (GLOBE NEWSWIRE) -- HDAC Inhibitor Market to Observe Stunning Growth During the Study Period (2020–2034) | DelveInsight According to DelveInsight’s analysis, the growth of the HDAC inhibitors market is expected
Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab
Morningstar· 4 days agoThe NDA is supported by results from JUPITER-02, a randomized, double...
Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML
Morningstar· 6 days agoKura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today ...
Innovent to Present Clinical Data of Multiple Novel Molecules at the 2024 ASCO Annual Meeting
Char-Koosta News· 4 days agoSAN FRANCISCO and SUZHOU, China, April 24, 2024 /PRNewswire/ -- Innovent Biologics, Inc....
Merck highlights progress on HIV, hypertension, cervical cancer drugs
WFMZ Eastern Pennsylvania and Western New Jersey· 3 days agoMerck got off to an excellent start in the first quarter of 2024. Wall Street met the news with...
Nisa Investment Advisors LLC Boosts Stock Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
ETF DAILY NEWS· 6 days agoNisa Investment Advisors LLC raised its stake in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 284.0% in the 4th quarter, according to the company in its most recent ...